secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0000950170-25-047755
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion Q4 net loss $29.3M; cash drops to $58.6M; interim CEO appointed, pivots to diabetes
--------------------------------------------------------------------------------

- Net loss $29.3M for Q4 2024 ($34.9M in Q4 2023); FY net loss $138.4M vs $117.3M.
- Cash reserves $58.6M at Dec 31, 2024, down from $177.2M a year earlier.
- Mick Hitchcock appointed interim CEO; all oncology trials terminated, focus shifts to diabetes/obesity.
- Icovamenib in severe insulin-deficient T2D: 1.47% HbA1c reduction at Week 26; FDA meeting planned H1 2025.
- BMF-650 (oral GLP-1 RA) IND submission planned H2 2025; preclinical appetite suppression data reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000095017025047755/0000950170-25-047755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000095017025047755/bmea-20250331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-047755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer